Incorporates an active component that will significantly shorten the treatment duration of MPE compared to current catheter devices.
A user-friendly design to promote patient independence, comfort and quality of life.
Reduces the costs associated with long-term home drainage and acute readmissions to hospital.
Posted in News by Symphysis Medical
5th December, 2022
SymPhysis Medical were delighted to be nominated for the Emerging Medtech Company of the Year Award at the Irish Medtech Awards in December 2022. The Irish Medtech Association is the...
Read more
Posted in News by Symphysis Medical
24th November, 2022
The SymPhysis Medical team were delighted to win Best Indigenous Healthcare Start-up at the The HealthTech Innovation Awards in Dublin on 23 November. HealthTech Ireland is an independent trade association for...
Read more
Posted in News by Symphysis Medical
1st November, 2022
In October 2022, SymPhysis Medical graduated from MedTech Innovator, a global accelerator program for medical device, digital health and diagnostic companies. Having won the highly competitive International Pitch event in Dublin...
Read morePosted in News by Mary Faherty
4th May, 2022
SymPhysis Medical were thrilled to win the MedTech Innovator Dublin International Pitch event, which took place in Dublin on 25 & 26 April 2022. MedTech Innovator is a global competition and...
Read more
Affects ~90% of patients with mesothelioma.
Affects ~ 35% of patients with lung cancer.
Affects ~ 16% of patients with breast cancer.
Affects ~ 11% of patients with lymphoma.
